Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis

Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis

Background: First-line treatments for nonsmall cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations have been evaluated in various clinical trials. However, it remains unclear which is the optimal treatment. Methods: A Bayesian network meta-analysis was used to assess...

Full description

Bibliographic Details
Main Authors: Zhonghan Zhang, Kangmei Zeng, Shen Zhao, Yuanyuan Zhao, Xue Hou, Fan Luo, Feiteng Lu, Yaxiong Zhang, Ting Zhou, Yuxiang Ma, Yunpeng Yang, Wenfeng Fang, Yan Huang, Li Zhang, Hongyun Zhao
Format: Article
Language:English
Published: SAGE Publishing 2019-12-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835919891652

Internet

https://doi.org/10.1177/1758835919891652

Similar Items